Advertisement
Screener

Orchestra BioMed Holdings, Inc. (OBIO) Graph

OBIO Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2020-06-30: Net income -$15.21K.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

OBIO revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Product$88.00KRevenue$88.00KCost of revenue$25.00KOperating income-$22.36MResearch & development$16.59MSelling, general& administrative$5.83MNet income-$23.76M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 1 month

Period endNet income
2020-06-30-$15.21K

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2026-06-30$88.00K$25.00K$16.59M$5.83M(m)-$23.75M
2026-03-31$110.00K$32.00K$15.78M$6.37M(m)-$20.69M
2025-12-31$30.92M*$51.00K*$16.82M*$7.29M*(m)$6.25M*
2025-09-30$861.00K$49.00K$14.03M$7.10M(m)-$20.83M
2025-06-30$836.00K$46.00K$13.85M$6.26M(m)-$19.36M
2025-03-31$868.00K$44.00K$13.48M$6.26M(m)-$18.75M
2024-09-30$987.00K$68.00K$11.60M$5.67M(m)-$15.43M
2024-06-30$778.00K$44.00K$11.13M$6.47M(m)-$15.98M
2024-03-31$620.00K$34.00K$9.11M$5.90M(m)-$13.46M
2023-09-30$419.00K$41.00K$8.56M$6.34M(m)-$13.32M
2023-06-30$915.00K$54.00K$8.50M$5.32M(m)-$12.05M
2023-03-31$1.16M$44.00K$8.25M$4.41M(m)-$10.94M
2022-09-30$1.16M$56.00K$5.90M$5.28M(m)-$10.28M
2022-06-30$401.00K$60.00K$5.03M$2.95M(m)-$7.85M
2022-03-31$866.00K$42.00K$3.47M$2.48M(m)-$5.73M
2021-09-30(m)(m)(m)(m)(m)-$90.41K
2021-06-30(m)(m)(m)(m)(m)-$92.33K
2021-03-31(m)(m)(m)(m)$111.95K-$108.00K
2020-09-30(m)(m)(m)(m)$68.63K-$66.21K

Revenue and expense 4 month

Period endOperating expensesNet income
2020-09-30$83.84K-$81.43K

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeNet income
2026-06-30$198.00K$57.00K$32.37M$12.20M-$44.45M
2025-06-30$1.70M$90.00K$27.34M$12.53M-$38.12M
2024-06-30$1.40M$78.00K$20.24M$12.36M-$29.44M
2023-06-30$2.08M$98.00K$16.75M$9.73M-$22.99M
2022-06-30$1.27M$102.00K$8.50M$5.42M-$13.58M
2021-06-30(m)(m)(m)(m)-$200.33K

Revenue and expense 7 month

Period endOperating expensesNet income
2020-12-31$179.99K(m)

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeNet income
2025-09-30$2.56M$139.00K$41.36M$19.63M-$58.95M
2024-09-30$2.38M$146.00K$31.83M$18.03M-$44.87M
2023-09-30$2.50M$139.00K$25.31M$16.07M-$36.30M
2022-09-30$2.43M$158.00K$14.40M$10.70M-$23.86M
2021-09-30(m)(m)(m)(m)-$290.74K

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-12-31$33.48M$190.00K$58.19M$26.91M$0.00-$52.70M
2024-12-31$2.64M$204.00K$42.80M$23.93M(m)-$61.02M
2023-12-31$2.76M$186.00K$33.82M$20.26M(m)-$49.12M
2022-12-31$3.53M$211.00K$21.95M$14.03M(m)-$33.61M
2021-12-31(m)(m)(m)(m)(m)-$378.75K

Similar stocks

Stock NameCountryMarket CapPE Ratio
SHOULDER INNOVATIONS, INC. (SI)United States$0.355B
Orthofix Medical Inc. (OFIX)$0.373B
Embecta Corp. (EMBC)United States$0.319B2.10
CARLSMED, INC. (CARL)United States$0.405B
TREACE MEDICAL CONCEPTS, INC. (TMCI)United States$0.297B-4.32
Mobia Medical, Inc. (MOBI)United States$0.293B
TriSalus Life Sciences, Inc. (TLSI)United States$0.283B-9.92
Cytosorbents Corp (CTSO)United States$0.274B-1.29
ORASURE TECHNOLOGIES INC (OSUR)United States$0.272B-6.26
Anika Therapeutics, Inc. (ANIK)United States$0.272B-51.71